Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeted, safe, and efficient gene delivery to human hematopoietic stem and progenitor cells in vivo using the engineered AVID adenovirus vector platform

Molecular Therapy(2023)10.1016/j.ymthe.2023.10.023Source: DataRank Database

Targeted, safe, and efficient gene delivery to human hematopoietic stem and progenitor cells in vivo using the engineered AVID adenovirus vector platform is a research paper published in Molecular Therapy (2023). On theSindex it has a DataRank of 0. It has been cited 18 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access18 citations

Download PDF

Cite:

Linked data & code

pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 3.81)OA: hybridTopics (44)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Svetlana Atasheva ORCID,Nicole Wagner ORCID,Nelson C. Di Paolo,Phoebe L. Stewart ORCID,Dmitry M. Shayakhmetov ORCID

Live enrichment

PubMed:37919899 PMC:PMC10787117 OpenAlex:https://openalex.org/W4388153915

NIAID NIH HHS

Grant: R37 AI107960

NCI NIH HHS

Grant: P30 CA138292

NCI NIH HHS

Grant: R01 CA267694

NIAID NIH HHS

Grant: R01 AI107960

FWCI

3.81

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.ymthe.2023.10.023

publisherhttps://doi.org/10.1016/j.ymthe.2023.10.023

publisherhttps://api.elsevier.com/content/article/PII:S1525001623006007?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525001623006007?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37919899

Fields of Study

Virus-based gene therapy researchCAR-T cell therapy researchCRISPR and Genetic EngineeringHumansAnimalsMiceHematopoietic Stem CellsGene Transfer TechniquesAntigens, CD34Genetic TherapyAdenoviridaeHematopoietic Stem Cell Transplantation

MeSH Terms

AdenoviridaeAnimalsHematopoietic Stem CellsHumansGenetic TherapyGene Transfer TechniquesHematopoietic Stem Cell TransplantationAntigens, CD34Mice

Keywords

Gene deliveryStem cellProgenitor cellCD34Viral vectorGenetic enhancementHaematopoiesisBiologyTransduction (biophysics)Hematopoietic stem cellIn vivoBone marrowCell biologyImmunologyGeneGeneticsGene therapyHematopoietic stem cellsAdenovirusIntravenous AdministrationVector TargetingVector EngineeringTargeted In vivo Delivery

Sustainable Development Goals

SDG 0: Good health and well-being

Targeted, safe, and efficient gene delivery to human hematopoietic stem and progenitor cells in vivo using the engineered AVID adenovirus vector platform

FAIR Checklist

Authors (6)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)